Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: kawamoto y. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Clinical characteristics and antimicrobial susceptibility of Eggerthella lenta infection over a 5-year trend at a university hospital in Japan.
Mori N, Nakamura A, Hirai J, Asai N, Shibata Y, Takayama M, Kawamoto Y, Miyazaki N, Sakanashi D, Ohno T, Yamada A, Suematsu H, Koita I, Chida S, Ohta T, Mikamo H. Mori N, et al. Among authors: kawamoto y. Nagoya J Med Sci. 2024 Nov;86(4):683-692. doi: 10.18999/nagjms.86.4.683. Nagoya J Med Sci. 2024. PMID: 39780922 Free PMC article.
Action Mechanisms of Exosomes Derived from GD3/GD2-Positive Glioma Cells in the Regulation of Phenotypes and Intracellular Signaling: Roles of Integrins.
Hasnat MA, Ohmi Y, Yesmin F, Kaneko K, Kambe M, Kitaura Y, Ito T, Imao Y, Kano K, Mishiro-Sato E, Koyanagi H, Kawamoto Y, Bhuiyan RH, Ohkawa Y, Tajima O, Furukawa K, Furukawa K. Hasnat MA, et al. Among authors: kawamoto y. Int J Mol Sci. 2024 Nov 27;25(23):12752. doi: 10.3390/ijms252312752. Int J Mol Sci. 2024. PMID: 39684463 Free PMC article.
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas. Imaoka H, et al. Among authors: kawamoto y. J Gastroenterol. 2024 Nov 30. doi: 10.1007/s00535-024-02186-9. Online ahead of print. J Gastroenterol. 2024. PMID: 39614927
Development of a Water-Soluble Nanomicellar Formulation Loaded with Trans-Resveratrol Using Polyethylene Glycol Monostearate for the Treatment of Intracerebral Hemorrhage.
Banshoya K, Machida A, Kawamura S, Yamada T, Okada R, Kawamoto Y, Kimura H, Shibata S, Hieda Y, Kaneo Y, Tanaka T, Ohnishi M. Banshoya K, et al. Among authors: kawamoto y. Pharmaceutics. 2024 Nov 15;16(11):1462. doi: 10.3390/pharmaceutics16111462. Pharmaceutics. 2024. PMID: 39598585 Free PMC article.
594 results